Cardio Diagnostics (NASDAQ:CDIO) Releases Earnings Results

Cardio Diagnostics (NASDAQ:CDIO) announced its earnings results on Friday. The company reported ($0.51) earnings per share (EPS) for the quarter, Zacks reports. Cardio Diagnostics had a negative return on equity of 78.82% and a negative net margin of 36,950.00%.

Cardio Diagnostics Price Performance

CDIO traded up $0.13 during trading hours on Friday, hitting $1.79. 6,433 shares of the stock were exchanged, compared to its average volume of 1,694,226. The stock has a market cap of $5.30 million, a price-to-earnings ratio of -0.53 and a beta of 2.27. The stock has a 50-day simple moving average of $1.88 and a 200-day simple moving average of $2.14. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Cardio Diagnostics stock. DRW Securities LLC lifted its holdings in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 122.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,463 shares of the company’s stock after buying an additional 22,298 shares during the period. DRW Securities LLC owned 2.21% of Cardio Diagnostics worth $110,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.06% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cardio Diagnostics presently has an average rating of “Sell”.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.